Opinion
Video
Author(s):
Experts on prostate cancer discuss the heterogeneity of the disease and the rationale for using medications with different mechanisms of action, including androgen deprivation therapy.
FDA Updates in Urology: January 2025
Dr. Murphy on increasing diversity in cancer clinical trials
Urologic Cancer Facts and Updates for World Cancer Day 2025
Dr. Schwen on focal therapies for prostate cancer
Acute toxicity after prostate cancer radiotherapy increases odds of late toxicity
MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine